UMV reports grants from Fond'Action; consulting fees (for advisory boards and symposia) from Dr Grasso Consulting, Kantonsspital Aaurau, Chur, Inselspital Bern, and SAMO (personal); consulting fees (for advisory boards and symposia) from Bayer, Astellas, Janssen-Cilag, Merck, Pfizer, MSD, BMS, Ipsen, and Novartis AAA (institutional); expert testimonials for Merck and BMS (institutional); and travel grants from Merck, Janssen-Cilag, and Ipsen. DM reports research grants from BMS, Exelixis, Merck, Genentech, Roche, Pfizer, X4 Pharma, Alkermes, and Eisai; and consulting fees (for advisory boards and membership of steering committees) from Roche, BMS, Exelixis, Merck EMD Serono, Eli Lilly and Company, Iovance, Calithera Biosciences, Johnson & Johnson, Aveo, Clinigen, MSD, Pfizer, Synthekine, Eisai, Alkermes, and Werewolf Therapuetics. TP reports grants from AstraZeneca, Roche, BMS, Exelixis, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, and Eisai; consulting fees (for advisory boards, symposia, and membership of steering committees) from AstraZeneca, Roche, BMS, Exelixis, Incyte, Ipsen, Merck, MSD, Novartis, Pfizer, Seattle Genetics, Merck Serono, Astellas, Johnson & Johnson, Eisai, and Mashup; and travel fees for attending meetings from Roche, Pfizer, MSD, AstraZeneca, and Ipsen. BMS, Roche, MSD, and Merck Serono all manufacture immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab, avelumab, and atezolizumab), which are discussed in this Comment, and the other listed companies above are unrelated to this topic but related to cancer research.